How to cite item

Multicenter Clinical Study for Evaluation of Efficacy and Safety of Transdermal Fentanyl Matrix Patch in Treatment of Moderate to Severe Cancer Pain in 474 Chinese Cancer Patients

   
@article{CJCR882,
	author = {Yu-lin Zhu and Guo-hong Song and Duan-qi Liu and Xi Zhang and Kui-feng Liu and Ai-hua Zang and Ying Cheng and Guo-chun Cao and Jun Liang and Xue-zhen Ma and Xin Ding and Bin Wang and Wei-lian Li and Zuo-wei Hu and Gang Feng and Jiang-jin Huang and Xiao Zheng and Shun-chang Jiao and Rong Wu and Jun Ren},
	title = {Multicenter Clinical Study for Evaluation of Efficacy and Safety of Transdermal Fentanyl Matrix Patch in Treatment of Moderate to Severe Cancer Pain in 474 Chinese Cancer Patients},
	journal = {Chinese Journal of Cancer Research},
	volume = {23},
	number = {4},
	year = {2012},
	keywords = {},
	abstract = {Objective: Although a new matrix formulation fentanyl has been used throughout the world for cancer pain management, few data about its efficacy and clinical outcomes associated with its use in Chinese patients have been obtained. This study aimed to assess the efficacy and safety of the new system in Chinese patients with moderate to severe cancer pain. Methods: A total of 474 patients with moderate to severe cancer pain were enrolled in this study and were treated with the new transdermal fentanyl matrix patch (TDF) up to 2 weeks. All the patients were asked to record pain intensity, side effects, quality of life (QOL), adherence and global satisfaction. The initial dose of fentanyl was 25 µg/h titrated with opioid or according to National Comprehensive Cancer Network (NCCN) guidelines. Transdermal fentanyl was changed every three days. Results: After 2 weeks. The mean pain intensity of the 459 evaluated patients decreased significantly from 5.631.26 to 2.031.46 (P<0.0001). The total remission rate was 91.29%, of which moderate remission rate 53.16%, obvious remission rate 25.49% and complete remission rate 12.64%. The rate of adverse events was 33.75%, 18.78% of which were moderate and 3.80% were severe. The most frequent adverse events were constipation and nausea. No fatal events were observed. The quality of life was remarkably improved after the treatment (P<0.0001). Conclusion: The new TDF is effective and safe in treating patients with moderate to severe cancer pain, and can significantly improve the quality of life.},
	issn = {1993-0631},	url = {https://cjcr.amegroups.org/article/view/882}
}